The pathophysiology of bone disease in gastrointestinal disease

European Journal of Gastroenterology and Hepatology

Volumn 15, Issue 8, 2003, Pages 857-864

  Bernstein, Charles N ^a,b   Leslie, William D ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b John Buhler Research Centre   (Canada)

Author keywords

Coeliac disease; Inflammatory bowel disease; Osteoblastogenesis; Osteoclastogenesis; Osteoporosis; Post gastrectomy state

Indexed keywords

CORTICOSTEROID; CYTOKINE; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR;

BONE DISEASE; BONE MASS; CELIAC DISEASE; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; GASTRECTOMY; GASTROINTESTINAL DISEASE; HUMAN; INFLAMMATION; MALNUTRITION; NUTRITIONAL STATUS; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; PATHOPHYSIOLOGY; POSTGASTRECTOMY SYNDROME; PRIORITY JOURNAL; REVIEW;

EID: 0041314021     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200308000-00004     Document Type: Review

References (108)

1. Alexeeva L, Burkhardt P, Christiansen C, Cooper C, Delmas P, Johnell O, et al. Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis: Report of a WHO Study Group. WHO Technical Report Series 843. Geneva: WHO; 1994. pp. 1-129.
2. Smith CB, Smith DA. Relations between age, mineral density and mechanical properties of human femoral compacta. Acta Orthop Scand 1976; 47:496-502.
3. Weinstein RS, Manolagas SC. Apoptosis and osteoporosis. Am J Med 2000; 108:153-164.
4. Heaney RP, Abrams S, Dawson-Hughes B, Looker A, Marcus R, Matkovic V, et al. Peak bone mass. Osteoporos Int 2000; 11:985-1009.
5. Stewart TL, Ralston SH. Role of genetic factors in the pathogenesis of osteoporosis. J Endocrinol 2000; 166:235-245.
6. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996; 11:337-349.
7. Vleggaar FP, van Buuren HR, Wolfhagen FHJ, Schalm SW, Pols HAP. Prevention and treatment of osteoporosis in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999; 11:617-621.
8. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15:993-1000. A very large general medical practice cohort study (244 235 oral corticosteroid users and 244 235 controls) which provides fracture risk estimates during and after oral corticosteroid treatment. There is a rapid offset of increased fracture risk by 3 months after cessation of therapy.
9. Sambrook PN, Eisman JA, Yeates MG, Pocock NA, Eberl S, Champion GD. Osteoporosis in rheumatoid arthritis: safety of low dose corticosteroids. Ann Rheum Dis 1986; 48:950-953.
10. Haddad JG Jr, Hahn TJ. Natural and synthetic sources of circulating 25-hydroxyvitamin D in man. Nature 1973; 244:515-516.
11. Preece MA, Tomlinson S, Ribot CA, Pietrek J, Korn HT, Davies DM, et al. Studies of vitamin D deficiency in man. Q J Med 1975; 44:575-589.
12. Vogelsang H, Schofl R, Tillinger W, Ferenci P, Gangl A. 25-Hydroxyvitamin D absorption in patients with Crohn's disease and with pancreatic insufficiency. Wien Klin Wochenschr 1997; 109:678-682.
13. Compston JE, Judd D, Crawley EO, Evans WD, Evans C, Church HA, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987; 28:410-415.
14. Andreassen H, Rungby J, Dahlerup JF, Mosekilde L. Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol 1997; 32:1247-1255.
15. Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J Intern Med 1996; 239:131-137.
16. Hessov I, Mosekilde L, Melsen F, Fasth S, Hulten L, Lund B, et al. Osteopenia with normal vitamin D metabolites after small-bowel resection for Crohn's disease. Scand J Gastroenterol 1984; 19:691-696.
17. Croucher PI, Vedi S, Motley RJ, Garrahan NJ, Stanton MR, Compston JE. Reduced bone formation in patients with osteoporosis associated with inflammatory bowel disease. Osteoporos Int 1993; 3:236-241. One of the few bone histomorphometry studies in inflammatory bowel disease (IBD) showing that osteomalacia is not a common problem.
18. Fickling WE, McFarlane XA, Bhalla AK, Robertson DAF. The clinical impact of metabolic bone disease in coeliac disease. Postgrad Med J 2001; 77:33-36.
19. Haden ST, Fuleihan GE, Angell JE, Cotran NM, LeBoff MS. Calcidiol and PTH levels in women attending an osteoporosis program. Calcif Tissue Int 1999; 64:275-279.
20. Thompson GR, Lewis B, Booth CC. Vitamin-D absorption after partial gastrectomy. Lancet 1966; i:457-458. Although often vitamin D absorption was initially considered to be altered postgastrectomy, this study refuted this notion.
21. Zittel TT, Zeeb B, Maier GW, Kaiser GW, Zwirner M, Liebich H, et al. High prevalence of bone disorders after gastrectomy. Am J Surg 1997; 174:431-438.
22. Bisballe S, Eriksen EF, Melsen F, Mosekilde L, Sorensen OH, Hessov I. Osteopenia and osteomalacia after gastrectomy: interrelations between biochemical markers of bone remodelling, vitamin D metabolites, and bone histomorphometry. Gut 1991; 32:1303-1307.
23. Mellstrom D, Johansson C, Johnell O, Lindstedt G, Lundberg PA, Obrant K, et al. Osteoporosis, metabolic aberrations, and increased risk for vertebral fractures after partial gastrectomy. Calcif Tissue Int 1993; 53:370-377.
24. Eddy RL. Metabolic bone disease after gastrectomy. Am J Med 1971; 50:442-449.
25. Morgan DB, Paterson CR, Woods CG, Pulvertaft CN, Fourman P. Osteomalacia after gastrectomy. A response to very small doses of vitamin D. Lancet 1965; ii:1089-1091.
26. Raisz LG. Local and systemic factors in the pathogenesis of osteoporosis. N Engl J Med 1988; 318:818-828.
27. Martin TJ, Ng KW, Suda T. Bone cell physiology. Endocrinol Metab Clin North Am 1989; 18:833-858.
28. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402:304-309.
29. Votta BJ, Bertolini DR. Cytokine suppressive anti-inflammatory compounds inhibit bone resorption in vitro. Bone 1994; 15:533-538.
30. Gilbert L, He X, Farmer P, Boden S, Kozlowski M, Rubin J, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 2000; 141:3956-3964.
31. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000; 275:4858-4864.
32. Kaji K, Katogi R, Azuma Y, Naito A, Inoue JI, Kudo A. Tumor necrosis factor alpha-induced osteoclastogenesis requires tumor necrosis factor receptor-associated factor 6. J Bone Miner Res 2001; 16:1593-1599.
33. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986; 319:516-518.
34. Thomson BM, Mundy GR, Chambers TJ. Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol 1987; 138:775-779.
35. Lader CS, Flanagan AM. Prostaglandin E2, interleukin 1alpha, and tumor necrosis factor-alpha increase human osteoclast formation and bone resorption in vitro. Endocrinology 1998; 139:3157-3164.
36. Kurokouchi K, Kambe F, Yasukawa K, Izumi R, Ishiguro N, Iwata H, et al. TNF-alpha increases expression of IL-6 and ICAM-1 genes through activation of NF-kappaB in osteoblast-like ROS17/2.8 cells. J Bone Miner Res 1998; 13:1290-1299.
37. Radeff JM, Nagy Z, Stern PH. Involvement of PKC-beta in PTH, TNF-alpha, and IL-1 beta effects on IL-6 promoter in osteoblastic cells and on PTH-stimulated bone resorption. Exp Cell Res 2001; 268:179-188.
38. Tsuboi M, Kawakami A, Nakashima T, Matsuoka N, Urayama S, Kawabe Y, et al. Tumor necrosis factor-alpha and interleukin-1 beta increase the Fas-mediated apoptosis of human osteoblasts. J Lab Clin Med 1999; 134:222-231. This study links proinflammatory cytokines known to be important in the intestinal inflammation of IBD and apoptosis of osteoblasts, thereby potentially providing one mechanism for osteoporosis secondary to the inflammatory response of IBD.
39. Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 2000; 11:905-913.
40. Kong YY, Boyle WJ, Penninger JM. Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. Immunol Cell Biol 1999; 77:188-193. This is an important report linking osteoclastogenesis and bone disease with systemic immunity and hence potentially with inflammatory states.
41. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12:1260-1268. This study unequivocally shows the importance of osteoprotegerin in maintaining bone mass.
42. Kong YY, Penninger JM. Molecular control of bone remodeling and osteoporosis. Exp Gerontol 2000; 35:947-956.
43. Lin CL, Moniz C, Chambers TJ, Chow JW. Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology 1996; 111:1263-1271.
44. Hyams JS, Wyzga N, Kreutzer DL, Justinich CJ, Gronowicz GA. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. J Pediatr Gastroenterol Nutr 1997; 24:289-295.
45. Przemioslo RT, Kontakou M, Nobili V, Ciclitira PJ. Raised pro-inflammatory cytokines interleukin 6 and tumour necrosis factor alpha in coeliac disease mucosa detected by immunohistochemistry. Gut 1994; 35:1398-1403.
46. Westerholm-Ormio M, Garioch J, Ketola I, Savilahti E. Inflammatory cytokines in small intestinal mucosa of patients with potential coeliac disease. Clin Exp Immunol 2002; 128:94-101.
47. Blanco QA, Arranz SE, Garrote Adrados JA, Oyaguez UP, Calvo RC, Alonso FM. The tumor necrosis factor system and leptin in coeliac disease. An Esp Pediatr 2001; 55:198-204.
48. Fornari MC, Pedreira S, Niveloni S, Gonzalez D, Diez RA, Vazquez H, et al. Pre- and post-treatment serum levels of cytokines IL-1 beta, IL-6, and IL-1 receptor antagonist in celiac disease. Are they related to the associated osteopenia? Am J Gastroenterol 1998; 93:413-418. The role of inflammatory cytokines in the osteopenia associated with coeliac disease is assessed in 16 women at the time of diagnosis (on an unrestricted diet) and after a mean time of 37 months on a gluten-free diet.
49. Thomas T, Burguera B. Is leptin the link between fat and bone mass? J Bone Miner Res 2002; 17:1563-1569.
50. Gordeladze JO, Drevon CA, Syversen U, Reseland JE. Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: impact on differentiation markers, apoptosis, and osteociastic signaling. J Cell Biochem 2002; 85:825-836. This paper reports an important connection between leptin, a regulator of body mass, and bone mineralization.
51. Holloway WR, Collier FM, Aitken CJ, Myers DE, Hodge JM, Malakellis M, et al. Leptin inhibits osteoclast generation. J Bone Miner Res 2002; 17:200-209. Leptin appears to mediate its anti-osteoclastic action through the RANKL/RANK/OPG system.
52. Ballinger A, Kelly P, Hallyburton E, Besser R, Farthing M. Plasma leptin in chronic inflammatory bowel disease and HIV: implications for the pathogenesis of anorexia and weight loss. Clin Sci (Lond) 1998; 94:479-483.
53. Hoppin AG, Kaplan LM, Zurakowski D, Leichtner AM, Bousvaros A. Serum leptin in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1998; 26:500-505.
54. Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995; 108:417-422.
55. Robinson RJ, Al Azzawi F, Iqbal SJ, Kryswcki T, Almond L, Abrams K, et al. Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci 1998; 43:2500-2506.
56. Robinson RJ, Carr I, Iqbal SJ, Al Azzawi F, Abrams K, Mayberry JF. Screening for osteoporosis in Crohn's disease. A detailed evaluation of calcaneal ultrasound. Eur J Gastroenterol Hepatol 1998; 10:137-140.
57. Schulte C, Dignass AU, Mann K, Goebell H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis 1998; 4:268-275.
58. Schoon EJ, Bick BM, Geerling BJ, Russel MG, Stockbrugger RW, Brummer RJM. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 2000; 119:1203-1208.
59. Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Porto GB. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J Intern Med 2000; 247:63-70.
60. Rannem T, Hylander E, Jarnum S, Ladefoged K, Schaadt O, Staun M, et al. Calcium absorption and bone mineral content in patients subjected to ileal bypass because of familial hypercholesterolaemia. Scand J Gastroenterol 1990; 25:897-905.
61. Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Rachmilewitz D. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease. Am J Gastroenterol 2000; 95:699-704.
62. Dinca M, Fries W, Luisetto G, Peccolo F, Bottega F, Leone L, et al. Evolution of osteopenia in inflammatory bowel disease. Am J Gastroenterol 1999; 94:1292-1297.
63. Mautalen C, Gonzalez D, Mazure R, Vazquez H, Lorenzetti MP, Maurino E, et al. Effect of treatment on bone mass, mineral metabolism, and body composition in untreated celiac disease patients. Am J Gastroenterol 1997; 92:313-318.
64. McFarlane XA, Bhalla AK, Reeves DE, Morgan LM, Robertson DA. Osteoporosis in treated adult coeliac disease. Gut 1995; 36:710-714.
65. Meyer D, Stavropolous S, Diamond B, Shane E, Green PHR. Ostecporosis in a North American adult population with celiac disease. Am J Gastroenterol 2001; 96:112-119.
66. Tovey FI, Hall ML, Ell PJ, Hobsley M. A review of postgastrectomy bone disease. J Gastroenterol Hepatol 1992; 7:639-645.
67. Schmiedl A, Schwille PO, Stuhler C, Gohl J, Rumenapf G. Low bone mineral density after total gastrectomy in males: a preliminary report emphasizing the possible significance of urinary net acid excretion, serum gastrin and phosphorus. Clin Chem Lab Med 1999; 37:739-744.
68. Pigot F, Roux C, Chaussade S, Hardelin D, Pelleter O, Du Puy MT, et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 1992; 37:1396-1403.
69. Clements D, Motley RJ, Evans WD, Harries AD, Rhodes J, Coles RJ, et al. Longitudinal study of cortical bone loss in patients with inflammatory bowel disease. Scand J Gastroenterol 1992; 27:1055-1060.
70. Roux C, Abitbol V, Chaussade S, Kolta S, Guillemant S, Dougados M, et al. Bone loss in patients with inflammatory bowel disease: a prospective study. Osteoporos Int 1995; 5:156-160.
71. Staun M, Tjellesen L, Thale M, Schaadt O, Jarnum S. Bone mineral content in patients with Crohn's disease. A longitudinal study in patients with bowel resections. Scand J Gastroenterol 1997; 32:226-232.
72. Bischoff SC, Herrmann A, Goke M, Manns MP, von zur MA, Brabant G. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 1997; 92:1157-1163.
73. Bjarnascn I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40:228-233.
74. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994; 107:1031-1039.
75. Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995; 10:250-256.
76. Andreassen H, Hylander E, Rix M. Gender, age, and body weight are the major predictive factors for bone mineral density in Crohn's disease: a case-control cross-sectional study of 113 patients. Am J Gastroenterol 1999; 94:824-828.
77. Ulivieri FM, Lisciandrano D, Ranzi T, Taioli E, Cermesoni L, Piodi LP, et al. Bone mineral density and body composition in patients with ulcerative colitis. Am J Gastroenterol 2000; 95:1491-1494.
78. Lee SH, Kim HJ, Yang SK, Kim WH, Joo YS, Dong SH, et al. Decreased trabecular bone mineral density in newly diagnosed inflammatory bowel disease patients in Korea. J Gastroenterol Hepatol 2000; 15:512-518.
79. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37:71-76.
80. Silvennoinen J, Lamberg-Allardt C, Karkkainen M, Niemela S, Lehtola J. Dietary calcium intake and its relation to bone mineral density in patients with inflammatory bowel disease. J Intern Med 1996; 240:285-292.
81. Teichmann J, Lange U, Stracke H, Doppl W, Klor HU, Federlin K. Rapid spinal trabecular bone loss in female patients with ileitis terminalis Crohn and additional sacroiliac joint inflammation. Rheumatol Int 1997; 17:45-48.
82. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut 1997; 40:313-319.
83. Schoon EJ, van Nunen AB, Wouters RSME, Stockbrugger RW, Russel MGVM. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol 2000; 35:43-47.
84. Robinson RJ, Iqbal SJ, Abrams K, Al Azzawi F, Mayberry JF. Increased bone resorption in patients with Crohn's disease. Aliment Pharmacol Ther 1998; 12:699-705.
85. Fries W, Dinca M, Luisetto G, Peccolo F, Bottega F, Martin A. Calcaneal ultrasound bone densitometry in inflammatory bowel disease - a comparison with double X-ray densitometry of the lumbar spine. Am J Gastroenterol 1998; 93:2339-2344.
86. Floren CH, Ahren B, Bengtsson M, Bartosik J, Obrant K. Bone mineral density in patients with Crohn's disease during long-term treatment with azathioprine. J Intern Med 1998; 243:123-126.
87. Kemppainen T, Kroger H, Janatuinen E, Arnala I, Kosma VM, Pikkarainen P, et al. Osteoporosis in adult patients with celiac disease. Bone 1999; 24:249-255.
88. Selby PL, Davies M, Adams JE, Mawer EB. Bone loss in celiac disease is related to secondary hyperparathyroidism. J Bone Miner Res 1999; 14:652-657.
89. Corazza GR, Di Stefano M, Jorizzo RA, Cecchetti L, Minguzzi L, Gasbarrini G. Propeptide of type I procollagen is predictive of posttreatment bone mass gain in adult celiac disease. Gastroenterology 1997; 113:67-71.
90. Corazza GR, Di Sario A, Cecchetti L, Jorizzo RA, Di Stefano M, Minguzzi L, et al. Influence of pattern of clinical presentation and of gluten-free diet on bone mass and metabolism in adult coeliac disease. Bone 1996; 18:525-530.
91. Keaveny AP, Freaney R, McKenna MJ, Masterson J, O'Donoghue DP. Bone remodeling indices and secondary hyperparathyroidism in celiac disease. Am J Gastroenterol 1996; 91:1226-1231.
92. Valdimarsson T, Lofman O, Toss G, Strom M. Reversal of osteopenia with diet in adult coeliac disease. Gut 1996; 38:322-327.
93. Corazza GR, Di Sario A, Cecchetti L, Tarozzi C, Corrac G, Bernardi M, et al. Bone mass and metabolism in patients with celiac disease. Gastroenterology 1995; 109:122-128.
94. Caraceni MP, Molteni N, Bardella MT, Ortolani S, Nogara A, Bianchi PA. Bone and mineral metabolism in adult celiac disease. Am J Gastroenterol 1988; 83:274-277.
95. Staun M, Jarnum S. Measurement of the 10,000-molecular weight calcium-binding protein in small-intestinal biopsy specimens from patients with malabsorption syndromes. Scand J Gastroenterol 1988; 23:827-832.
96. Valdimarsson T, Arnqvist HJ, Toss G, Jarnerot G, Nystrom F, Strom M. Low circulating insulin-like growth factor I in coeliac disease and its relation to bone mineral density. Scand J Gastroenterol 1999; 34:904-908.
97. Jameson S. Coeliac disease, insulin-like growth factor, bone mineral density, and zinc. Scand J Gastroenterol 2000; 35:894-896.
98. Devine A, Rosen C, Mohan S, Baylink D, Prince RL. Effects of zinc and other nutritional factors on insulin-like growth factor I and insulin-like growth factor binding proteins in postmenopausal women. Am J Clin Nutr 1998; 68:200-206.
99. Thompson GR. Vitamin D deficiency after gastrectomy. Sci Basis Med Annu Rev 1970; 260-275.
100. Hakanson R, Persson P, Axelson J, Johnell O, Sundler F. Evidence that gastrin enhances 45Ca uptake into bone through release of a gastric hormone. Regul Pept 1990; 28:107-118.
101. Rumenapf G, Schwille PO, Erben RG, Schreiber M, Berge B, Fries W, et al. Gastric fundectomy in the rat: effects on mineral and bone metabolism, with emphasis on the gastrin-calcitonin-parathyroid hormone-vitamin D axis. Calcif Tissue Int 1998; 63:433-441.
102. Fries W, Rumenapf G, Schwille PO. Disturbances of mineral and bone metabolism following gastric antrectomy in the rat. Bone Miner 1992; 19:245-256.
103. Recker RR. Calcium absorption and achlorhydria. N Engl J Med 1985; 313:70-73.
104. Adachi Y, Shiota E, Matsumata T, Iso Y, Yoh R, Kitano S. Bone mineral density in patients taking H2-receptor antagonist. Calcif Tissue Int 1998; 62:283-285.
105. Blichert-Toft M, Beck A, Christiansen C, Transbol I. Effects of gastric resection and vagotomy on blood and bone mineral content. World J Surg 1979; 3:99-105.
106. 2D on calcium homeostasis and bone mineral content after gastric surgery. Calcif Tissue Int 1985; 37:461-466.
107. Marcinowska-Suchowierska EB, Talalaj MJ, Wlodarcyzk AW, Bielecki K, Zawadzki JJ, Brzozowski R. Calcium/phosphate/vitamin D homeostasis and bone mass in patients after gastrectomy, vagotomy, and cholecystectomy. World J Surg 1995; 19:597-601.
108. Kong Y-Y, Boyle WJ, Penninger JM. Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today 2000; 21:495-502.